免疫检查点治疗——现状与未来方向。
Immune checkpoint therapy-current perspectives and future directions.
机构信息
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006.
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimize patient selection to maximize efficacy and minimize toxicities prompted efforts to unravel immune and non-immune factors regulating the responses to ICT. This review highlights the biology of anti-tumor immunity underlying response and resistance to ICT, discusses efforts to address the current challenges with ICT, and outlines strategies to guide the development of subsequent clinical trials and combinatorial efforts with ICT.
免疫检查点疗法（ICT）显著改变了癌症患者的临床结局，并带来了持久的临床获益，包括部分患者的治愈。不同肿瘤类型的反应率不同，以及需要预测性生物标志物来优化患者选择，以最大限度地提高疗效和最小化毒性，这促使人们努力揭示调节 ICT 反应的免疫和非免疫因素。本综述强调了 ICT 反应和耐药性的抗肿瘤免疫生物学，讨论了应对 ICT 当前挑战的努力，并概述了指导后续临床试验和与 ICT 联合治疗发展的策略。
Zotero 插件